<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3596">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04584580</url>
  </required_header>
  <id_info>
    <org_study_id>FMASU P35/ 2020</org_study_id>
    <nct_id>NCT04584580</nct_id>
  </id_info>
  <brief_title>D-dimer Adjusted Versus Therapeutic Dose Low-molecular-weight Heparin in Patients With COVID-19 Pneumonia</brief_title>
  <official_title>D-dimer Adjusted Versus Therapeutic Dose Low-molecular-weight Heparin in Patients With COVID-19 Pneumonia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ain Shams University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ain Shams University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      evaluation of the efficacy and safety of D-dimer adjusted heparin versus therapeutic dose&#xD;
      heparin in patients with COVID-19 Pneumonia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The following will be done for enrolled patients:&#xD;
&#xD;
        1. Data collection: name, age, sex, special habits of medical importance (i.e. smoking,&#xD;
           drug abuse), comorbid conditions.&#xD;
&#xD;
        2. Clinical examination Vital data Local chest examination&#xD;
&#xD;
        3. Measurement of oxygen saturation using pulse oximeter&#xD;
&#xD;
        4. Laboratory investigations:&#xD;
&#xD;
           Complete blood count with differential count Liver and kidney functions D-dimer level&#xD;
           Coagulation profile&#xD;
&#xD;
        5. Radiology work up ( Chest X-ray-High resolution computed tomography of the chest-&#xD;
           computed tomography of the chest with pulmonary angiography as needed)&#xD;
&#xD;
        6. Sepsis-induced coagulopathy score (SIC score)&#xD;
&#xD;
        7. Sequential organ failure score (SOFA score)&#xD;
&#xD;
        8. Patients will receive treatment according to the hospital guidelines for different&#xD;
           disease stratification severity&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>mortality</measure>
    <time_frame>Until patient is discharged or up to 4 weeks whichever comes first</time_frame>
    <description>All cause mortality</description>
  </primary_outcome>
  <primary_outcome>
    <measure>occurrence of venous and/or arterial thrombosis</measure>
    <time_frame>Until patient is discharged or up to 4 weeks whichever comes first</time_frame>
    <description>clinical signs supported by radiological evidence of arterial thrombosis or venous thromboembolism (e.g. venous or arterial duplex and CT scan of the chest with pulmonary angiography)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>occurrence of Sepsis-induced coagulopathy</measure>
    <time_frame>Until patient is discharged or up to 4 weeks whichever comes first</time_frame>
    <description>calculation of sepsis induced coagulopathy (SIC) score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of adult respiratory distress syndrome (ARDS)</measure>
    <time_frame>Until patient is discharged or up to 4 weeks whichever comes first</time_frame>
    <description>Calculation of partial pressure of arterial oxygen/ fraction of inspired oxygen (PaO2/ FIO2) ratio</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of sepsis</measure>
    <time_frame>Until patient is discharged or up to 4 weeks whichever comes first</time_frame>
    <description>Calculation of sequential organ failure (SOFA) score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU admission and need for mechanical ventilation</measure>
    <time_frame>Until patient is discharged or up to 4 weeks whichever comes first</time_frame>
    <description>occurrence of respiratory failure detected by arterial blood gases analysis</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Coronavirus Disease (COVID)19</condition>
  <arm_group>
    <arm_group_label>Therapeutic dose low-molecular-weight heparin (LMWH)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Therapeutic dose low-molecular-weight heparin from admission until the end of hospital stay Enoxaparin 1 mg/kg subcutaneous every 12 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>D-dimer levels and weight adjusted low-molecular-weight heparin (LMWH)therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>from admission until the end of hospital stay. Patients will be stratified according to their body weight and D-dimer level and receive LMWH&#xD;
D-Dimer level Body Weight LMWH dose&#xD;
&lt;1 mg/dl &lt;100kg Enoxaparin 40mg OD 100-150kg Enoxaparin 40mg BD &gt;150kg Enoxaparin 60mg BD&#xD;
1-3 mg/ dl &lt;100kg Enoxaparin 40mg BD 100-150kg Enoxaparin 80mg BD &gt;150kg Enoxaparin 120mg BD&#xD;
&gt;3 mg/ dl Enoxaparin 80mg BD</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>low-molecular-weight heparin</intervention_name>
    <description>low-molecular-weight heparin administered via subcutaneous injection</description>
    <arm_group_label>D-dimer levels and weight adjusted low-molecular-weight heparin (LMWH)therapy</arm_group_label>
    <arm_group_label>Therapeutic dose low-molecular-weight heparin (LMWH)</arm_group_label>
    <other_name>Enoxaparin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All adult (&gt;18 years) patients from both sexes with COVID-19 pneumonia with positive&#xD;
             nucleic acid test for severe acute respiratory syndrome Coronavirus (SARS-CoV-2)&#xD;
             hospitalized either in the ward or intensive care unit&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with absolute contraindication of pharmacological thromboprophylaxis and/&#xD;
             anticoagulation&#xD;
&#xD;
          -  Congenital hemorrhagic disorders&#xD;
&#xD;
          -  Hypersensitivity to heparin&#xD;
&#xD;
          -  Personal history of heparin-induced thrombocytopenia&#xD;
&#xD;
          -  Active major bleeding or conditions predisposing to major bleeding. Major bleeding is&#xD;
             defined as fulfilling any one of these three criteria: a) occurs in a critical area or&#xD;
             organ (e.g.intracranial, intraspinal, intraocular, retroperitoneal, intra-articular or&#xD;
             pericardial, intra-uterine or intramuscular with compartment syndrome), b) causes a&#xD;
             fall in haemoglobin level (Hb) of ≥2g/dL in a 24h period, or c) leads to transfusion&#xD;
             of 2 or more units of whole blood or red blood cells (13).&#xD;
&#xD;
          -  Suspected or confirmed bacterial endocarditis&#xD;
&#xD;
          -  Ongoing or planned therapeutic anticoagulation for any other indication&#xD;
&#xD;
          -  Platelet count &lt;50,000/μL within the past 24 hours or Hb level &lt;8g/dL&#xD;
&#xD;
          -  Prothrombin time (PT) ≥2 seconds above the upper limit of age-appropriate local&#xD;
             reference range within the past 24 hours&#xD;
&#xD;
          -  Activated partial thromboplastin time (aPTT) ≥4 seconds above the upper limit of&#xD;
             age-appropriate local reference range within the past 24 hours&#xD;
&#xD;
          -  Fibrinogen &lt;2.0 g/L&#xD;
&#xD;
          -  Severe renal impairment (CrCl&lt;30 mL/min) or acute kidney injury&#xD;
&#xD;
          -  Use of dual antiplatelet therapy&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Unwillingness to consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ashraf Madkour</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ain Shams University, Faculty of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ashraf Madkour</last_name>
    <phone>+20 100 177 0703</phone>
    <email>asfrah_madkour@yahoo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Faculty of Medicine Ain Shams University Research Institute- Clinical Research Center</name>
      <address>
        <city>Cairo</city>
        <state>Non-US</state>
        <zip>11566</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fatma Soliman E Ebeid</last_name>
      <phone>01095569596</phone>
      <email>dr.fatma_ebeid@yahoo.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 6, 2020</study_first_submitted>
  <study_first_submitted_qc>October 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 14, 2020</study_first_posted>
  <last_update_submitted>October 10, 2020</last_update_submitted>
  <last_update_submitted_qc>October 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ain Shams University</investigator_affiliation>
    <investigator_full_name>Ashraf M Madkour</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heparin</mesh_term>
    <mesh_term>Enoxaparin</mesh_term>
    <mesh_term>Heparin, Low-Molecular-Weight</mesh_term>
    <mesh_term>Tinzaparin</mesh_term>
    <mesh_term>Dalteparin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

